Other research reported that genetic as well as pharmacological inhibition of EphA4 signaling increases survival in a disease modifier of amyotrophic lateral sclerosis (ALS) (Van Hoecke et al., 2012). This evidence concerns the gene EPHA4 and amyotrophic lateral sclerosis.